Apps

openserveblockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

IJR News — today's news from every side

Novo Nordisk Tests Lower Wegovy Doses — Aug 19, 2026Novo Nordisk is conducting a late-stage study to identify the lowest effective dose of Wegovy, testing two low doses against placebo in 450 participants as it seeks to preserve its share in a obesity drug market projected to exceed $100 billion annually by 2030. The trial, which began on August 12 and runs through 2028, follows competitive pressure from Eli Lilly and comes after Wegovy's recent sales performance, with dose strengths undisclosed.